Main Conference Day 3 - European Time GMT+1
- Janine Schuurman, Ph.D. - Biotech Consultant, Lust for Life Science
- James Ernst, Ph.D. - Vice President, Development Sciences; Head of Protein Sciences & Technology, Xencor
- Darko Skegro, PhD - Director and Site Head, Biotherapeutic Engineering and Conjugation, Novartis
Ficerafusp alfa, is a first-in-class EGFR-TGF-b bifunctional antibody. TGF-β signaling within the tumor microenvironment (TME) creates fibrotic, immunosuppressive barriers that impede tumor penetration of immune cells. Mechanistic insights from paired biopsies and preclinical studies reveal the importance of tumor targeted inhibition of TGF- b in breaking down barriers to tumor penetration. Ultimately, ficerafusp alfa’s tumor penetration has the potential to drive deep and durable responses that lead to long-term clinical benefits.
- Brenda O'Connell - Senior Director, Translational Science, Bicara Therapeutics
TAVO412 is an avidity driven trispecific antibody that engages multiple mechanisms of action to control different resistance mechanisms in solid tumors. We describe confirmation of target engagement in Phase 1A trials for patients struggling with mutant lung, esophageal, and colorectal cancers. In addition, we highlight the pharmacokinetic profiles, tolerability, and clinical responses.
- Mark Chiu, PhD - Co-founder - Entrepreneur, Qilin Glen LLC
- Simone Oostindie - Director, Research and Discovery, Gyes BV
- Alexey Lugovskoy, PhD - President and CEO, Diagonal Therapeutics
Adeno-associated virus (AAV) gene therapies face challenges in tissue-specific delivery and safety. We have developed bispecific Altibody for precise AAV retargeting to muscle and CNS. This innovative "plug-and-play" approach enhances on-target transduction efficacy and safety in mice, marking a milestone in AAV retargeting strategies for gene therapy applications.
- Yang Shen, PhD - Executive Director, Antibody Engineering & Bispecifics, Regeneron